Primary Site >> Colorectal Cancer

Gene >> IL2

  • 1985
  • 1986
  • 1987
  • 1988
  • 1989
  • 1990
  • 1991
  • 1992
  • 1993
  • 1994
  • 1995
  • 1996
  • 1997
  • 1998
  • 1999
  • 2000
  • 2001
  • 2002
  • 2003
  • 2004
  • 2005
  • 2006
  • 2007
  • 2008
  • 2009
  • 2010
  • 2011
  • 2012
  • 2013
  • 2014
  • 2015
  • 2016
  • 2017
  • 2018
Ref: Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors.
PMID: 2989604
Ref: Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer.
PMID: 3871657
Ref: Interleukin generation in experimental colon cancer of rats: effects of tumor growth and tumor therapy.
PMID: 3872959
Ref: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.
PMID: 3903508
Ref: Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells.
PMID: 3917475
Ref: Lymphokine-activated and natural killer cell activity in human intestinal mucosa.
PMID: 3926882
Ref: [In vitro enhancement of cytotoxicity of human peripheral blood lymphocytes with recombinant interleukin 2 and an interferon mixture (alpha + beta + gamma) against human colon carcinoma cell line SW1116].
PMID: 3098183
Ref: Production of and response to interleukin-2 in peripheral blood lymphocytes of cancer patients.
PMID: 3484660
Ref: A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2.
PMID: 3526604
Ref: Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies.
PMID: 2437198
Ref: Characterization of an immunosuppressive factor derived from colon cancer cells.
PMID: 3104453
Ref: Therapy of cancer using the adoptive transfer of activated killer cells and interleukin-2.
PMID: 3124451
Ref: Reduced incidence of hepatic metastases by perioperative treatment with recombinant human interleukin-2.
PMID: 3496196
Ref: Human tumor cell lines with pleiotropic drug resistance are efficiently killed by interleukin-2 activated killer cells and by activated monocytes.
PMID: 3496283
Ref: Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells.
PMID: 3496958
Ref: In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2.
PMID: 3500355
Ref: In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors.
PMID: 2446744
Ref: An 80 to 85 kilodalton human phosphoglycoprotein associated with cell activation.
PMID: 3183379
Ref: Susceptibility of chemoresistant murine and human tumor cells to lysis by interleukin 2-activated lymphocytes.
PMID: 3258541
Ref: Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.
PMID: 3259261
Ref: [Adoptive immunotherapy of malignant disease using LAK cells].
PMID: 3260466
Ref: Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
PMID: 3260537
Ref: Interleukin 1 promotes tumor cell adhesion to cultured human endothelial cells.
PMID: 3262629
Ref: The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells.
PMID: 3264128
Ref: Lymphokine-activated killer (LAK) cells from human intestinal mucosa: cytotoxic activity against tumor cell lines and modified self but not autologous and allogeneic colon cancer cells.
PMID: 3361887
Ref: Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro.
PMID: 2462468
Ref: [Adoptive immunotherapy of advanced cancer patients with immune RNA-sensitized lymphocytes].
PMID: 2479817
Ref: Cytostatic and cytotoxic activity of lymphokine-activated killer cell supernatants.
PMID: 2480843
Ref: Combination therapy of colon carcinoma 26 in mice with recombinant human interleukin-2 and interferon-alpha A/D: occurrence of large granular cells in the tumor.
PMID: 2513305
Ref: Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.
PMID: 2647914
Ref: A monoclonal antibody (D612) with selective reactivity for malignant and normal gastro-intestinal epithelium.
PMID: 2649441
Ref: Recombinant interleukin-2 by continuous infusion and adoptive transfer of recombinant interleukin-2-activated cells in patients with advanced cancer.
PMID: 2661733
Ref: A phase-II trial of recombinant interleukin-2 and 5-FU chemotherapy in patients with metastatic colorectal carcinoma.
PMID: 2670212
Ref: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.
PMID: 2679456
Ref: Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells.
PMID: 2783243
Ref: Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukemia, and selected solid tumors.
PMID: 2783339
Ref: Characterization of activated lymphocytes in colon cancer.
PMID: 2783402
Ref: A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions.
PMID: 2783732
Ref: Influence of the donors' clinical status on in vitro and in vivo tumor-cytotoxic activation of interleukin-2-exposed lymphocytes and their circulation in different organs.
PMID: 2783888
Ref: Murine monoclonal IgG3 to human colorectal tumor-associated antigens: enhancement of antibody-dependent cell-mediated cytotoxicity by interleukin 2.
PMID: 2785437
Ref: Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplastic diseases.
PMID: 2786553
Ref: Adriamycin-induced resistance to natural killer (NK)-mediated cytotoxicity.
PMID: 2786743
Ref: Tolerance and effectiveness of recombinant interleukin-2 (r-met Hu IL-2 [ala-125]) and lymphokine-activated killer cells in patients with metastatic solid tumors.
PMID: 2787749
Ref: Treatment of patients with advanced cancer using multiple long-term cultured lymphokine-activated killer (LAK) cell infusions and recombinant human interleukin-2.
PMID: 2795092
Ref: Lymphokine-activated killer cell induction in tumor-infiltrating leukocytes from colon cancer patients.
PMID: 2804913
Ref: Selective immunosuppressive action of a factor produced by colon cancer cells.
PMID: 1698119
Ref: The clinical significance of interleukin-2.
PMID: 2092277
Ref: Swainsonine, an inhibitor of glycoprotein processing, enhances cytotoxicity of large granular lymphocytes.
PMID: 2108487
Ref: Lymphokine-activated killer cell cytotoxicity against human colon carcinomas enhanced by monoclonal antibody D612.
PMID: 2123477
Ref: Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response.
PMID: 2137372
Ref: Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A).
PMID: 2199042
Ref: Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity.
PMID: 2213099
Ref: Phase I study of interleukin-2 and interferon alfa-2a as outpatient therapy for patients with advanced malignancy.
PMID: 2213102
Ref: Paradoxical effects of 5-FU/folinic acid on lymphokine-activated killer (LAK) cell induction in patients with colorectal cancer.
PMID: 2257211
Ref: Suppression of tumor cell growth and mitogen response by aporphine alkaloids, dicentrine, glaucine, corydine, and apomorphine.
PMID: 2290126
Ref: Tumor-infiltrating lymphocytes from human colon carcinomas. Functional and phenotypic characteristics after long-term culture in recombinant interleukin 2.
PMID: 2295382
Ref: Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes. Survival benefit of adjuvant post-surgical treatments and comparison with experimental m
PMID: 2306753
Ref: Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study.
PMID: 2334534
Ref: Evaluation of tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumor cytotoxicity.
PMID: 2340518
Ref: Time course of changes in phenotypes of cultured tumor-infiltrating lymphocytes isolated from human colorectal cancer.
PMID: 2347471
Ref: Chimeric B72.3 mouse/human (IgG1) antibody directs the lysis of tumor cells by lymphokine-activated killer cells.
PMID: 2386980
Ref: Natural killer cell stimulatory factor (NKSF) augments natural killer cell and antibody-dependent tumoricidal response against colon carcinoma cell lines.
PMID: 1673486
Ref: The high lysability by LAK cells of colon-carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM-1, LFA-3, NCA and a less-differentiated phenotype.
PMID: 1706327
Ref: Molecular and functional analysis of human natural killer cell-associated neural cell adhesion molecule (N-CAM/CD56).
PMID: 1710251
Ref: Cell surface expression of ICAM-1 (CD54) and LFA-3 (CD58), two adhesion molecules, is up-regulated on bone marrow leukemic blasts after in vivo administration of high-dose recombinant interleukin-2.
PMID: 1722705
Ref: Lymphokine-activated killer-cell-mediated killing of WiDr colon carcinoma cells is inhibited by K562 erythroleukemia cells.
PMID: 1756146
Ref: Therapeutic use of a long-term cytotoxic T cell line recognizing a common tumour-associated antigen: the pattern of in vitro reactivity predicts the in vivo effect on different tumours.
PMID: 1760812
Ref: Adjuvant adoptive immunotherapy with IL2 and lymphocytes from tumor-bearing mice: in vitro tumor-stimulated lymphocytes are more effective than LAK cells.
PMID: 1787836
Ref: Immunological effects of levamisole in vitro.
PMID: 1790137
Ref: Relapse after response to interleukin-2-based immunotherapy: patterns of progression and response to retreatment.
PMID: 1790145
Ref: Factors influencing the establishment of tumour-infiltrating lymphocyte cultures from human breast carcinoma and colon carcinoma tissue.
PMID: 1827279
Ref: Immunotherapy with IL2 by constant infusion and weekly doxorubicin.
PMID: 1830717
Ref: Human recombinant interleukin-6 enhances antibody-dependent cellular cytotoxicity of human tumor cells mediated by human peripheral blood mononuclear cells.
PMID: 1836975
Ref: Effects of cytokines on in vitro growth of tumor-infiltrating lymphocytes obtained from human primary and metastatic liver tumors.
PMID: 1847844
Ref: Treatment of chemically induced autochthonous rat mammary and colorectal carcinomas with interleukin-2.
PMID: 1868493
Ref: Immunotherapy of cancer with lymphokines and lymphokine-activated killer cells.
PMID: 1925249
Ref: Decrease in cholesterol levels during the immunotherapy of cancer with interleukin-2.
PMID: 1931624
Ref: Intestinal lymphokine-activated killer cells in inflammatory bowel disease.
PMID: 1932665
Ref: Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.
PMID: 1933892
Ref: [Splenic or hepatic arterial injections of interleukin-2 with chemotherapeutic agents for hepatic metastases].
PMID: 1944193
Ref: Hypovitaminosis C in patients treated with high-dose interleukin 2 and lymphokine-activated killer cells.
PMID: 1962585
Ref: Characterization of the colorectal carcinoma-associated antigen defined by monoclonal antibody D612.
PMID: 1988133
Ref: Recombinant interleukin-2: a biological response modifier.
PMID: 2009728
Ref: Human lymphokine-activated killer cells augment immunotherapy of human colon carcinoma xenografts with monoclonal antibody D612.
PMID: 2012797
Ref: Substance P increases in vitro lymphokine-activated-killer (LAK) cell cytotoxicity against fresh colorectal cancer cells.
PMID: 1279274
Ref: Neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin as a second-line treatment in metastatic colorectal carcinoma.
PMID: 1297233
Ref: Human c-erbB-2 proto-oncogene product as a target for bispecific-antibody-directed adoptive tumor immunotherapy.
PMID: 1347516
Ref: Establishment of cytotoxic CD4+ T cell clones from cancer patients treated by local immunotherapy.
PMID: 1363274
Ref: Effect of anti-CD3 antibody on the generation of interleukin-2-activated lymphocytes from tumor tissues of gastrointestinal cancer.
PMID: 1386555
Ref: Perioperative immunotherapy with recombinant interleukin 2 in patients undergoing surgery for colorectal cancer.
PMID: 1394200
Ref: Impaired cytokine production in whole blood cell cultures from patients with colorectal carcinomas as compared to benign colorectal tumors and controls.
PMID: 1403351
Ref: Effects of a preoperative therapy with interleukin-2 on surgery-induced lymphocytopenia in cancer patients.
PMID: 1495748
Ref: Immunotherapy of colorectal cancer.
PMID: 1511394
Ref: Interleukin-2 increases the antibody response in patients receiving autologous intralymphatic tumor cell vaccine immunotherapy.
PMID: 1515096
Ref: Immunopathological changes in the skin following recombinant interleukin-2 treatment.
PMID: 1517903
Ref: Resident research award: tumor necrosis factor alpha selectively enhances growth and cytotoxic activity of tumor infiltrating lymphocytes from human colorectal cancer.
PMID: 1548866
Ref: Interleukin-2 followed by fluorouracil and folinic acid in refractory colorectal cancer--results of a clinical phase II study.
PMID: 1557653
Ref: IL-2 production by intestinal lamina propria cells in normal inflamed and cancer-bearing colons.
PMID: 1563100
Ref: Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.
PMID: 1596937
Ref: Phase I study of low-dose cyclophosphamide and recombinant interleukin-2 for the treatment of advanced cancer.
PMID: 1599914
Ref: Clinical trials of intrasplenic arterial infusion of interleukin-2 (IS-IL-2) to patients with advanced cancer.
PMID: 1622739
Ref: Cytotoxic activity of intestinal lamina propria lymphocytes on human immunodeficiency virus (HIV)-infected cells.
PMID: 1628889
Ref: Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas.
PMID: 1729379
Ref: The treatment of colorectal hepatic metastases by continuous local infusion of interleukin-2.
PMID: 21584588
Ref: Immunogenicity of recombinant human interleukin-2: biological features and clinical relevance.
PMID: 7517168
Ref: Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo.
PMID: 7683166
Ref: Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.
PMID: 7693434
Ref: Enhanced activity against syngeneic murine tumors by intrasplenic injection of recombinant interleukin-2 (IL-2) and interleukin-1 (IL-1).
PMID: 7804373
Ref: [Treatment with butyrate/IL-2 combination in peritoneal carcinomatosis of colonic origin].
PMID: 8019883
Ref: Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatonin.
PMID: 8023699
Ref: Immunotherapy with low-dose subcutaneous interleukin-2 plus beta-interferon as a second-line therapy for metastatic colorectal carcinoma.
PMID: 8116079
Ref: Expansion of tumor-infiltrating lymphocytes from human tumors using the T-cell growth factors interleukin-2 and interleukin-4.
PMID: 8280717
Ref: A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and Pseudomonas exotoxin.
PMID: 8314773
Ref: T-cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model: III. Activation of resting T cells and tumor neutralization induced by bispecific antibodies.
PMID: 8334106
Ref: Synergetic effect of interleukin-2 and cellular cytotoxicity against a novel tumor-associated carbohydrate antigen Le(a)/Le(a) (dimeric Le(a)) mediated by monoclonal antibody NCC-ST-421 in adoptive immunization using SCID mice.
PMID: 8348564
Ref: Therapeutic effect of neuraminidase-treated LAK cells on liver metastasis of Colon 26.
PMID: 8379346
Ref: Short-duration in vitro interleukin-2-activated mononuclear cells for advanced cancer. A Hong Kong biotherapy pilot study trial.
PMID: 8387882
Ref: T-cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model: IV. Tumor neutralization in Winn type assays.
PMID: 8399065
Ref: Peri-operative modulation of cellular immunity in patients with colorectal cancer.
PMID: 8403515
Ref: Specific immune recognition of autologous tumor by lymphocytes infiltrating colon carcinomas: analysis by cytokine secretion.
PMID: 8422663
Ref: T cell killing of human colon carcinomas by monoclonal-antibody-targeted superantigens.
PMID: 8439985
Ref: T cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model. II. Syngeneic colon carcinoma CC531 is efficiently killed by retargeted cytotoxic T lymphocytes in vitro despite limited lysis in 51Cr release assays.
PMID: 8450213
Ref: Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience.
PMID: 8453558
Ref: [Characterization of autologous-tumor specific cytotoxic T cells induced by means of butanol-extracted soluble antigen from T lymphocytes in colon cancer patients].
PMID: 8464410
Ref: Renal toxicity mediated by continuous infusion of recombinant interleukin-2.
PMID: 8502315
Ref: The expression and biological activity of IL-2 receptor on a human pancreas cancer cell line.
PMID: 8507543
Ref: Superantigen-induced cytokines suppress growth of human colon-carcinoma cells.
PMID: 8509223
Ref: Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract.
PMID: 8512825
Ref: Inhibition of proliferation, activation and function of human natural-killer-cells in-vitro by secreted products of lovo, a colorectal-cancer cell-line.
PMID: 21573430
Ref: [Observation of the effects of LAK/IL-2 therapy combining with Lycium barbarum polysaccharides in the treatment of 75 cancer patients].
PMID: 7720497
Ref: Growth inhibition of human gastrointestinal cancer cells by cyclosporin A.
PMID: 7798292
Ref: Single-chain antibody variable region-targeted interleukin-2 stimulates T cell killing of human colorectal carcinoma cells.
PMID: 7806260
Ref: The clinical experience with interleukin-2 in cancer therapy.
PMID: 7820182
Ref: A phase II study of advanced colorectal cancer patients treated with combination 5-fluorouracil plus leucovorin and subcutaneous interleukin-2 plus alpha interferon.
PMID: 7830105
Ref: Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors.
PMID: 7834121
Ref: Chimeric (mouse/human) anti-colon cancer antibody c30.6 inhibits the growth of human colorectal cancer xenografts in scid/scid mice.
PMID: 7954462
Ref: An interleukin 2/sodium butyrate combination as immunotherapy for rat colon cancer peritoneal carcinomatosis.
PMID: 7958681
Ref: The decreased expression of CD3 zeta chains in cancer patients is not reversed by IL-2 administration.
PMID: 7989113
Ref: Interleukin 2 treatment in colorectal cancer: current results and future prospects.
PMID: 7995410
Ref: Complete remission of liver metastases from colorectal cancer by treatment with a hepatic artery infusion (HAI) of interleukin-2-based immunochemotherapy: reports of three cases.
PMID: 8054783
Ref: Enhanced cell-mediated tumor killing in patients immunized with human monoclonal antiidiotypic antibody 105AD7.
PMID: 8069847
Ref: A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinoma.
PMID: 8110733
Ref: The infiltration of experimentally induced lung metastases of colon carcinoma CC531 by adoptively transferred interleukin-2-activated natural killer cells in Wag rats.
PMID: 8112894
Ref: Colon adenocarcinoma cells inhibit anti-CD3-activated killer cell induction.
PMID: 8124689
Ref: Impaired left ventricular filling rate induced by treatment with recombinant interleukin 2 for advanced cancer.
PMID: 8130026
Ref: Effects of oral administration of Lactobacillus casei on antitumor responses induced by tumor resection in mice.
PMID: 8150553
Ref: Functional role of IL-2 receptors on tumour-infiltrating lymphocytes.
PMID: 8198969
Ref: In vivo cytokine production and recombinant interleukin 2 immunotherapy: an insight into the possible mechanisms underlying clinical responses.
PMID: 8198981
Ref: Influence of cytokines on mdr1 expression in human colon carcinoma cell lines: increased cytotoxicity of MDR relevant drugs.
PMID: 8207045
Ref: Growth inhibition of a colonic adenocarcinoma cell line (HT29) by T cells specific for mutant p21 ras.
PMID: 8306368
Ref: Perioperative immunomodulation in cancer surgery.
PMID: 8311130
Ref: Antibody-targeted lymphokine-activated killer cells inhibit liver micrometastases in severe combined immunodeficient mice.
PMID: 7498661
Ref: Acute phase proteins and recombinant IL-2 therapy: prediction of response and survival in patients with colorectal cancer.
PMID: 7531626
Ref: Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients.
PMID: 7539133
Ref: Phase I-II randomized study on prehepatectomy recombinant interleukin-2 immunotherapy in patients with metastatic carcinoma of the colon and rectum.
PMID: 7551323
Ref: Immunization against a rat colon carcinoma by sodium butyrate-treated cells but not by interleukin 2-secreting cells.
PMID: 7557139
Ref: Cytokine gene therapy with interleukin-2-transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity.
PMID: 7578396
Ref: Comparison of gene therapy with interleukin-2 gene modified fibroblasts and tumor cells in the murine CT-26 model of colorectal carcinoma.
PMID: 7582256
Ref: Effect of splenectomy on hepatic metastasis of colon carcinoma and natural killer activity in the liver.
PMID: 7587821
Ref: Effect of ranitidine and low-dose interleukin-2 in vitro on NK-cell activity in peripheral blood from patients with liver metastases from colorectal cancer.
PMID: 7589599
Ref: The role of cytokines in mediating the bystander effect using HSV-TK xenogeneic cells.
PMID: 7600527
Ref: Generation of lymphokine-activated killer (LAK) cell activity from malignant peritoneal effusions.
PMID: 7624448
Ref: Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine.
PMID: 7629885
Ref: Lymphocytes infiltrating colorectal cancer have low proliferative capacity but can secrete normal levels of interferon gamma.
PMID: 7641220
Ref: Morphological and functional characteristics of tumor-infiltrating lymphocytes from human colorectal cancers after stimulation with rIL-2.
PMID: 7649213
Ref: Expansion of mucin-reactive T-helper lymphocytes from patients with colorectal cancer.
PMID: 7663570
Ref: Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth.
PMID: 7674335
Ref: Tumor-associated glycoantigen, sialyl Lewis(a) as a target for bispecific antibody-directed adoptive tumor immunotherapy.
PMID: 7721341
Ref: Polysaccharide preparation PSK augments the proliferation and cytotoxicity of tumor-infiltrating lymphocytes in vitro.
PMID: 7762991
Ref: Identification of a monoclonal antibody, TV-1, directed against the basement membrane of tumor vessels, and its use to enhance the delivery of macromolecules to tumors after conjugation with interleukin 2.
PMID: 7780984
Ref: Induction of tumor-specific cytotoxic T lymphocytes and natural killer cells by tumor cells transfected with the interleukin-2 gene.
PMID: 7828164
Ref: Superantigen-induced human CD4+ helper/killer T cell phenomenon. Selective induction of Th1 helper/killer T cells and application to tumor immunotherapy.
PMID: 7836762
Ref: Tumour-infiltrating lymphocytes bear the 75 kDa tumour necrosis factor receptor.
PMID: 7841036
Ref: Phase I trial of escalating doses of interleukin-1 beta in combination with a fixed dose of interleukin-2.
PMID: 7844609
Ref: Modulation of the cytokine and acute-phase response to major surgery by recombinant interleukin-2.
PMID: 7881967
Ref: The involvement of transforming growth factor beta in the impaired antitumor T-cell response at the gut-associated lymphoid tissue (GALT).
PMID: 8521406
Ref: Pre-operative interleukin-2 immunotherapy induces eosinophilic infiltration in colorectal neoplastic stroma.
PMID: 8532404
Ref: Culture of tumour-infiltrating lymphocytes from melanoma and colon carcinoma: removal of tumour cells does not affect tumour-specificity.
PMID: 8536275
Ref: Human, recombinant interleukin-2 induces in vitro histamine release in a dose-dependent manner.
PMID: 8590893
Ref: Development of immunogenic colorectal cancer cell lines for vaccination: expression of CD80 (B7.1) is not sufficient to restore impaired primary T cell activation in vitro.
PMID: 8652275
Ref: A phase II trial of interleukin-2 and interferon-alpha in the treatment of metastatic colorectal carcinoma.
PMID: 8680653
Ref: Sequential biochemotherapy for metastatic colorectal cancer using fluorouracil, folinic acid, thymopentin and interleukin-2: clinical and immunological effects.
PMID: 8750154
Ref: Efficacy and tolerability of cancer neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin - a progress report of 200 patients with advanced solid neoplasms.
PMID: 21597854
Ref: Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma.
PMID: 8566049
Ref: Murine colon carcinoma cells engineered to produce human interleukin-2 induce tumor-specific anti-tumor response.
PMID: 8608957
Ref: Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience.
PMID: 8621219
Ref: Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2.
PMID: 8625312
Ref: Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression.
PMID: 8625361
Ref: Interleukin-12 increases bispecific-antibody-mediated natural killer cell cytotoxicity against human tumors.
PMID: 8625370
Ref: Cytokine regulation of ezrin expression in the human colon cancer cell line HT29.
PMID: 8687142
Ref: Preoperative interleukin-2 subcutaneous immunotherapy may prolong the survival time in advanced colorectal cancer patients.
PMID: 8692528
Ref: [Vaccination with genetically modified IL-2 secreting cells in a rat model of colonic carcinoma].
PMID: 8695924
Ref: Adjuvant hepatic arterial IL-2 and MMC, 5-FU after curative resection of colorectal liver metastases.
PMID: 8799416
Ref: Subcutaneous low-dose interleukin-2 and intravenous 5-fluorouracil plus high-dose levofolinic acid as salvage treatment for metastatic colorectal carcinoma.
PMID: 8826605
Ref: Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells.
PMID: 8827016
Ref: [Diagnosis and therapy for metastatic liver cancer].
PMID: 8831736
Ref: Immune reactions induced by interleukin-2 transfected colorectal cancer cells in vitro: predominant induction of lymphokine-activated killer cells.
PMID: 8834769
Ref: Structure and function of sinusoidal lining cells in the liver.
PMID: 8839287
Ref: [Locoregional therapy for liver metastases of colorectal cancer].
PMID: 8854772
Ref: [Regional adoptive immunotherapy using activated lymphocytes].
PMID: 8854802
Ref: Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach for reversal of multidrug resistance.
PMID: 8912533
Ref: Diabetes mellitus induced by low-dose interleukin-2.
PMID: 8917637
Ref: Immunological and side effects of low sc recombinant interleukin-2 dose in addition to conventional treatment in relapsed breast and colorectal cancer patients.
PMID: 8952853
Ref: Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines.
PMID: 8955204
Ref: Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer.
PMID: 8980407
Ref: Release of cytokines by a fermented lectin-1 (ML-1) free mistletoe extract reflects differences in the reactivity of PBMC in healthy and allergic individuals and tumour patients.
PMID: 9010693
Ref: Inhibition of peritoneal dissemination of colon carcinoma in syngeneic mice immunized with interleukin-2-producing cells.
PMID: 9020917
Ref: The cognitive effects of recombinant interleukin-2 (rIL-2) therapy: a controlled clinical trial using computerised assessments.
PMID: 9038610
Ref: [A retrospective view of tumor immunology].
PMID: 9224970
Ref: Development of tumor B-cell lymphocyte hybridoma (TBH) autovaccination. Results of a phase I-II clinical trial.
PMID: 10168565
Ref: Prognostic significance of immunological evaluation in colorectal cancer.
PMID: 10851496
Ref: Necessity of biotherapeutic treatments inducing TH1 cell functions in colorectal cancer.
PMID: 10851498
Ref: Immunological directives for biotherapy improvement in the treatment of colorectal cancer.
PMID: 10851527
Ref: Cell mediated cytotoxicity of human colon carcinoma cells by a monoclonal antibody (R4) recognizing the carcinoembryonic antigen (CEA) and CEA-related molecules.
PMID: 21544473
Ref: Interleukin-7 (IL-7) in colorectal cancer: IL-7 is produced by tissues from colorectal cancer and promotes preferential expansion of tumour infiltrating lymphocytes.
PMID: 9042431
Ref: Histocompatibility leukocyte antigen-A2402-restricted cytotoxic T lymphocytes recognizing adenocarcinoma in tumor-infiltrating lymphocytes of patients with colon cancer.
PMID: 9119749
Ref: Cytotoxic T-cell clone against rectal carcinoma induced by stimulation of a patient's peripheral blood mononuclear cells with autologous cultured tumor cells.
PMID: 9139862
Ref: [Preoperative subcutaneous immunotherapy with interleukin-2 in renal carcinoma with synchronous metastasis: randomized clinico-biological study. Preoperative use of Il-2 in renal carcinoma].
PMID: 9181906
Ref: Expression of beta-galactoside alpha 2,6-sialyltransferase does not alter the susceptibility of human colon cancer cells to NK-mediated cell lysis.
PMID: 9184831
Ref: Modulations of the effector function and cytokine production of human lymphocytes by secreted factors derived from colorectal-carcinoma cells.
PMID: 9212235
Ref: Postoperative changes in serum interleukin-2 concentrations.
PMID: 9248982
Ref: Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats.
PMID: 9259401
Ref: Trefoil peptide expression and secretion is regulated by neuropeptides and acetylcholine.
PMID: 9277413
Ref: Interleukin-2-activated killer cell activity in colorectal tumor patients: evaluation of in vitro effects by prothymosin alpha1.
PMID: 9292704
Ref: Oncogene and cytokine expression of human colorectal tumors responding to immunotherapy.
PMID: 9336744
Ref: Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy.
PMID: 9354462
Ref: 5-Fluorouracil-resistant colonic tumors are highly responsive to sodium butyrate/interleukin-2 bitherapy in rats.
PMID: 9399677
Ref: Long-term survival of immunocompetent rats with intraperitoneal colon carcinoma tumors using herpes simplex thymidine kinase/ganciclovir and IL-2 treatments.
PMID: 9425438
Ref: The psychological and psychiatric effects of rIL-2 therapy: a controlled clinical trial.
PMID: 9451748
Ref: Anticancer neuroimmunomodulation by pineal hormones other than melatonin: preliminary phase II study of the pineal indole 5-methoxytryptophol in association with low-dose IL-2 and melatonin.
PMID: 9498162
Ref: Preclinical studies with prothymosin alpha1 on mononuclear cells from tumor patients.
PMID: 9637344
Ref: Various functions of PBMC from colon cancer patients are not decreased compared to healthy blood donors.
PMID: 10851450
Ref: The sCEA molecule suppressive role in NK and TH1 cell functions in colorectal cancer.
PMID: 10851473
Ref: The role of the soluble CD30 serum level in colorectal cancer: a possible marker for a patient subset which could benefit from IL-2 biotherapy.
PMID: 10851480
Ref: IL-2-Activated Killer Cells and Native Cytokines in Treatment of Patients with Advanced Cancer.
PMID: 12687071
Ref: Apoptosis induced by sodium butyrate treatment increases immunogenicity of a rat colon tumor cell line.
PMID: 14646537
Ref: Effects of thymic peptides, in vitro, on the impaired immunocytotoxicity of peripheral blood mononuclear cells from tumor patients.
PMID: 21533400
Ref: Interleukin-2 (IL-2) gene therapy with allogeneic fibroblasts in the CT-26 model of murine colorectal carcinoma.
PMID: 21590028
Ref: Low molecular thymic peptides improve the deficient immunocytotoxicity of mononuclear cells from tumor patients in vitro.
PMID: 21590251
Ref: The significance of an increase in soluble interleukin-2 receptor level in colorectal cancer and its biological regulating role in the physiological switching of the immune response cytokine network from TH1 to TH2 and back.
PMID: 9439647
Ref: Regional administration of natural killer cells in a rat hepatic metastasis model results in better tumor infiltration and anti-tumor response than systemic administration.
PMID: 9462713
Ref: Docetaxel treatment of HT-29 colon carcinoma cells reinforces the adhesion and immunocytotoxicity of peripheral blood lymphocytes in vitro.
PMID: 9499461
Ref: Molecular mimicry of carcinoembryonic antigen by peptides derived from the structure of an anti-idiotype antibody.
PMID: 9515808
Ref: Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+ CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene.
PMID: 9536262
Ref: Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer.
PMID: 9563485
Ref: Immune response of rat spleen cells to a carcinogen and to vaccination with anti-p53 polyclonal antibodies.
PMID: 9568090
Ref: Interleukin 2 restores CD3-zeta chain expression but fails to generate tumour-specific lytic activity in tumour-infiltrating lymphocytes derived from human colorectal hepatic metastases.
PMID: 9569042
Ref: Inhibition of experimental lung metastasis of murine colon carcinoma cells depends on the amount of interleukin-2 secreted from the transduced cells.
PMID: 9615724
Ref: Gene therapy for hepatic micrometastasis of murine colon carcinoma.
PMID: 9625325
Ref: Tumour necrosis factor-alpha enhances intraepithelial lymphocyte proliferation and migration.
PMID: 9659158
Ref: Recombinant immunocytokines targeting the mouse transferrin receptor: construction and biological activities.
PMID: 9667950
Ref: Colon cancer cell vaccine prepared with replication-deficient vaccinia viruses encoding B7.1 and interleukin-2 induce antitumor response in syngeneic mice.
PMID: 9690454
Ref: [Clinical evaluation of intermittent hepatic arterial infusion therapy for metastatic liver tumor of gastric and colorectal cancer].
PMID: 9703838
Ref: Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases.
PMID: 9731503
Ref: Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele.
PMID: 9732698
Ref: Selective suppression of cytokine secretion in whole blood cell cultures of patients with colorectal cancer.
PMID: 9792144
Ref: Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus.
PMID: 9824618
Ref: Induction of antigen presentation by macrophages after phagocytosis of tumour apoptotic cells.
PMID: 9851522
Ref: Anti-metastatic and immunomodulating properties of the water extract from Celosia argentea seeds.
PMID: 9853404
Ref: Immunocytokines: a promising approach to cancer immunotherapy.
PMID: 9888698
Ref: Comparison of the effects of various clinically applied mistletoe preparations on peripheral blood leukocytes.
PMID: 9893935
Ref: Inhibition of peritoneal dissemination of murine colon carcinoma cells by administrating retrovirus harboring IL-2 gene.
PMID: 9917087
Ref: IL-2 gene transfer for chemosensitization of multidrug-resistant human colon carcinoma cells.
PMID: 10026864
Ref: Local expression of cytokines in human colorectal carcinoma: evidence of specific interleukin-6 gene expression.
PMID: 9924696
Ref: T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice.
PMID: 10049944
Ref: Activated natural killer cell tumor retention and cytokine production in colon tumor using a tissue-isolated model.
PMID: 10068530
Ref: Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy.
PMID: 10086330
Ref: Inhibitory effects of transforming growth factor-beta (TGF-beta) on certain functions of intraepithelial lymphocytes.
PMID: 10193412
Ref: Enhancement of antibody dependent cellular cytotoxicity (ADCC) by combination of cytokines.
PMID: 10211790
Ref: Combined antitumour activity of mitomycin C, 5-fluorouracil and interleukin-2 against human colon cancer cells.
PMID: 10226560
Ref: Acquired immunity in nude mice induced by expression of the IL-2 or IL-4 gene in human pancreatic carcinoma cells and anti-tumor effect generated by in vivo gene transfer using retrovirus.
PMID: 10404069
Ref: Effects of immunization with tumor cells double transfected with interleukin-2 (IL-2) and interleukin-12 (IL-12) genes on artificial metastasis of colon26 cells in BALB/c mice.
PMID: 10411104
Ref: Expression of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cytokines (interleukin 2 and interferon gamma): inhibition by immunoglobulin a complexes.
PMID: 10449520
Ref: T cell memory against colon carcinoma is long-lived in the absence of antigen.
PMID: 10490962
Ref: Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: a Phase I study.
PMID: 10499605
Ref: Pre-operative IL-2 immunoprophylaxis of cancer recurrence: long-term clinical results of a phase II study in radically operable colorectal cancer.
PMID: 10523681
Ref: Effect of B7.1-transfected human colon cancer cells on the induction of autologous tumour-specific cytotoxic T cells.
PMID: 10530496
Ref: Antitumor effects of interleukin-2 gene-modified fibroblasts in an orthotopic colon cancer model.
PMID: 10551331
Ref: Recognition of a shared human prostate cancer-associated antigen by nonclassical MHC-restricted CD8+ T cells.
PMID: 10570328
Ref: Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma.
PMID: 10576658
Ref: Modulation of CD4 cell cytokine production by colon cancer-associated mucin.
PMID: 10602890
Ref: Synergistic antitumour effects of chemo-immunotherapy with an oxazaphosphorine drug and IL-2-secreting cells in a mouse colon cancer model.
PMID: 10618690
Ref: Influence of peri-operative immunotherapy on serum cytokines and soluble cytokine receptors in patients undergoing surgery for colorectal cancer.
PMID: 23577850
Ref: 105Ad7 cancer vaccine stimulates anti-tumour helper and cytotoxic T-cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responses.
PMID: 10585589
Ref: Comparison of the effects of immunosuppressive factors from newly established colon carcinoma cell cultures on human lymphocyte proliferation and cytokine secretion.
PMID: 10601837
Ref: Construction of new amplifier expression vectors for high levels of IL-2 gene expression.
PMID: 10677573
Ref: Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2.
PMID: 10685663
Ref: IL-10 enhances IL-2-induced proliferation and cytotoxicity by human intestinal lymphocytes.
PMID: 10691913
Ref: Adenovirus-mediated lymphotactin gene transfer improves therapeutic efficacy of cytosine deaminase suicide gene therapy in established murine colon carcinoma.
PMID: 10694814
Ref: Interleukin-18 in combination with IL-2 enhances natural killer cell activity without inducing large amounts of IFN-gamma in vivo.
PMID: 10714558
Ref: Combinations of the cytokines IL-12, IL-2 and IFN-alpha significantly augment whereas the cytokine IL-4 suppresses the cytokine-induced antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2.
PMID: 10843759
Ref: Augmentation of 17-1A-induced antibody-dependent cellular cytotoxicity by the triple cytokine combination of interferon-alpha, interleukin-2, and interleukin-12.
PMID: 10916758
Ref: Recombinant adenoviral vectors have adjuvant activity and stimulate T cell responses against tumor cells.
PMID: 10981668
Ref: Cytokines secreted by lymphokine-activated killer cells induce endogenous nitric oxide synthesis and apoptosis in DLD-1 colon cancer cells.
PMID: 11006006
Ref: Prestimulation of monocytes by the cytokines GM-CSF or IL-2 enhances the antibody dependent cellular cytotoxicity of monoclonal antibody 17-1A.
PMID: 11031784
Ref: Abrogation of surgery-induced decline in circulating dendritic cells by subcutaneous preoperative administration of IL-2 in operable cancer patients.
PMID: 11037053
Ref: Interleukin-2 enhances susceptibility of colon cancer cells to FasR mediated apoptosis by up-regulating Fas receptor level and down-regulating FAP-1 expression.
PMID: 12657200
Ref: What to do with targeted IL-2.
PMID: 12861355
Ref: Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression.
PMID: 11167991
Ref: The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy.
PMID: 11245457
Ref: Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice.
PMID: 11300483
Ref: Alteration of interleukin 2 (IL-2) pharmacokinetics and function by IL-2 antibodies induced after treatment of colorectal carcinoma patients with a combination of monoclonal antibody 17-1A, granulocyte macrophage colony-stimulating factor, and IL-2.
PMID: 11350880
Ref: Tributyrin enhances the cytotoxic activity of interleukin-2/interleukin-12 stimulated human natural killer cells against LS 174T colon cancer cells in vitro.
PMID: 11401027
Ref: Antitumor activity of expanded human tumor-infiltrating gammadelta T lymphocytes.
PMID: 11490159
Ref: Molecular genetics of ulcerative colitis-associated colon cancer in the interleukin 2- and beta(2)-microglobulin-deficient mouse.
PMID: 11559569
Ref: A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice.
PMID: 11591784
Ref: Combination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancer.
PMID: 11591892
Ref: MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma.
PMID: 11731434
Ref: A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-do
PMID: 11742494
Ref: [Receptors of selected cytokines and angiokine bFGF in patients with colorectal cancer (a preliminary study)].
PMID: 11852807
Ref: Abrogation of surgery-induced IL-6 hypersecretion by presurgical immunotherapy with IL-2 and its importance in the prevention of postoperative complications.
PMID: 11860226
Ref: Therapeutic effect of colon tumor cells expressing FLT-3 ligand plus systemic IL-2 in mice with syngeneic colon cancer.
PMID: 11904730
Ref: Recombinant interleukin-2 treatment decreases P-glycoprotein activity and paclitaxel metabolism in mice.
PMID: 11914641
Ref: Secretion of interleukin-10 from murine colon carcinoma cells suppresses systemic antitumor immunity and impairs protective immunity induced against the tumors.
PMID: 11916240
Ref: Effects of IL-2 preoperative immunotherapy on surgery-induced changes in angiogenic regulation and its prevention of VEGF increase and IL-12 decline.
PMID: 11995457
Ref: Low-dose recombinant IL-2 induces psychological changes: monitoring by Minnesota Multiphasic Personality Inventory (MMPI).
PMID: 12014643
Ref: Treatment with GM-CSF and IL-2 in patients with metastatic colorectal carcinoma induced high serum levels of neopterin and sIL-2R, an indicator of immune suppression.
PMID: 12070712
Ref: Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection.
PMID: 12439917
Ref: Adjuvant effect of a Flt3 ligand (FL) gene-transduced xenogeneic cell line in a murine colon cancer model.
PMID: 12443727
Ref: [Hepatic arterial infusion of IL-2 and chemotherapy for unresectable liver metastasis from colorectal cancer].
PMID: 12484016
Ref: [Cytokines and soluble cytokine receptors in the perioperative period].
PMID: 12688152
Ref: Cytokine associated sensitivity of colon carcinoma cells to FasR-mediated cytotoxicity of CTL.
PMID: 17585452
Ref: [Adoptive immunotherapy in malignant tumors].
PMID: 12608084
Ref: Interleukin-2 activated NK cells do not use the CD95L- and TRAIL-pathways in the rapid induction of apoptosis of rat colon carcinoma CC531s cells.
PMID: 12675269
Ref: Plasmid DNA encoding human carcinoembryonic antigen (CEA) adsorbed onto cationic microparticles induces protective immunity against colon cancer in CEA-transgenic mice.
PMID: 12706680
Ref: Comments on augmentation of local antitumor immunity in liver by interleukin-2 gene transfer via portal vein: a possible explanation for contradictory in vivo and vitro results of interleukin-2 treatment in a rat model of colon carcinoma metastasis.
PMID: 12719713
Ref: Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity.
PMID: 12782590
Ref: Synergistic effect of a granulocyte-macrophage colony-stimulating factor-transduced tumor vaccine and systemic interleukin-2 in the treatment of murine colorectal cancer hepatic metastases.
PMID: 12900373
Ref: Immune changes in patients with colorectal cancer treated by adjuvant therapy with monoclonal antibody 17-1A: a pilot study.
PMID: 12962368
Ref: Colon polyps and cytokines: emerging immunological mechanisms.
PMID: 14502322
Ref: Passage from normal mucosa to adenoma and colon cancer: alteration of normal sCD30 mechanisms regulating TH1/TH2 cell functions.
PMID: 14503949
Ref: Locoregional immunotherapy of malignant effusion from colorectal cancer using the streptococcal preparation OK-432 plus interleukin-2: induction of autologous tumor-reactive CD4+ Th1 killer lymphocytes.
PMID: 14612896
Ref: Effects of dietary folate on ulcerative colitis-associated colorectal carcinogenesis in the interleukin 2- and beta(2)-microglobulin-deficient mice.
PMID: 14652292
Ref: Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.
PMID: 14662896
Ref: Comparative evaluation of immune response after laparoscopical and open total mesorectal excisions with anal sphincter preservation in patients with rectal cancer.
PMID: 14669314
Ref: A psychoncological study of lymphocyte subpopulations in relation to pleasure-related neurobiochemistry and sexual and spiritual profile to Rorschach's test in early or advanced cancer patients.
PMID: 15065761
Ref: In situ recruitment of antigen-presenting cells by intratumoral GM-CSF gene delivery.
PMID: 12955480
Ref: Further development of local IL-2 therapy of cancer: multiple versus single IL-2 treatment of transplanted murine colon carcinoma.
PMID: 14770269
Ref: Host-oriented peptide evaluation using whole blood assay for generating antigen-specific cytotoxic T lymphocytes.
PMID: 15154646
Ref: Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial.
PMID: 15173076
Ref: The pattern of cytokine gene expression in human colorectal carcinoma.
PMID: 15188028
Ref: Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice.
PMID: 15256474
Ref: Adequate nourishment through total parenteral nutrition treatment may augment immune function in patients with colon cancer.
PMID: 15325502
Ref: Immunodeficiency in different histotypes of radically operable gastrointestinal cancers.
PMID: 15354402
Ref: Suppression of cancer cachexia by 20S,21-epoxy-resibufogenin-3-acetate-a novel nonpeptide IL-6 receptor antagonist.
PMID: 15381112
Ref: [Variation of cytokines with administration of chemotherapeutic and immuno-therapeutic drugs for colorectal cancer].
PMID: 15553673
Ref: The effect of Edrecolomab (Mo17-1A) or fluorouracil-based chemotherapy on specific immune parameters in patients with colorectal cancer. A comparative study.
PMID: 15713997
Ref: [Clinical role of interleukin-2 in the surgical treatment of liver metastasis due to colon adenocarcinoma].
PMID: 15876991
Ref: Immune responses in advanced colorectal cancer following repeated intradermal vaccination with the anti-CEA murine monoclonal antibody, PR1A3: results of a phase I study.
PMID: 15864608
Ref: Nucleofection of non-B cells with mini-Epstein-Barr virus DNA.
PMID: 16055146
Ref: Induction of mucosal and systemic immune responses against human carcinoembryonic antigen by an oral vaccine.
PMID: 16061685
Ref: Feasibility study of adoptive immunotherapy for metastatic lung tumors using peptide-pulsed dendritic cell-activated killer (PDAK) cells.
PMID: 16080467
Ref: Cytokine expression in colon carcinoma.
PMID: 16158955
Ref: Suppression of progression and metastasis of established colon tumors in mice by intravenous delivery of short interfering RNA targeting KITENIN, a metastasis-enhancing protein.
PMID: 16204073
Ref: 5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine.
PMID: 16204693
Ref: Evaluation of the antitumor activity of interleukin-12 in an experimental murine model of colorectal cancer induced by 1,2 dimethyl-hydrazine (DMH).
PMID: 16266234
Ref: [Dendritic cells reduce the number and function of CD4+CD25+ cells in cytokine-induced killer cells].
PMID: 16405818
Ref: CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice.
PMID: 16044253
Ref: Morphological appearance, content of extracellular matrix and vascular density of lung metastases predicts permissiveness to infiltration by adoptively transferred natural killer and T cells.
PMID: 16047144
Ref: Tumor necrosis factor-alpha and interferon-gamma increase PepT1 expression and activity in the human colon carcinoma cell line Caco-2/bbe and in mouse intestine.
PMID: 16328452
Ref: Combination cancer therapy by hapten-targeted prodrug-activating enzymes and cytokines.
PMID: 16704208
Ref: Reverse of NK cytolysis resistance of type II cytokine predominant-human tumor cells.
PMID: 16714222
Ref: Pre-operative immunoprophylaxis with interleukin-2 may improve prognosis in radical surgery for colorectal cancer stage B-C.
PMID: 16739327
Ref: Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent.
PMID: 16818703
Ref: Changes in hepatic immunoregulatory cytokines in patients with metastatic colorectal carcinoma: implications for hepatic anti-tumour immunity.
PMID: 16971136
Ref: In vivo migration of labeled autologous natural killer cells to liver metastases in patients with colon carcinoma.
PMID: 17105663
Ref: Cancer chemotherapy-induced lymphocytosis: a revolutionary discovery in the medical oncology.
PMID: 18088552
Ref: Transcriptionally targeted nonviral gene transfer using a beta-catenin/TCF-dependent promoter in a series of different human low passage colon cancer cells.
PMID: 17274670
Ref: Consumption of prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis has minor effects on selected immune parameters in polypectomised and colon cancer patients.
PMID: 17349080
Ref: Locoregional IL-2 therapy in the treatment of colon cancer. Cell-induced lesions of a murine model.
PMID: 17465231
Ref: Ex vivo optical coherence tomography and laser-induced fluorescence spectroscopy imaging of murine gastrointestinal tract.
PMID: 17536618
Ref: Thymosin alpha 1: from bench to bedside.
PMID: 17600290
Ref: [Immunotherapy in radical surgery of colorectal carcinoma].
PMID: 18019635
Ref: Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas.
PMID: 17764010
Ref: Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity.
PMID: 18422755
Ref: Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen.
PMID: 18467257
Ref: A study of immunoendocrine strategies with pineal indoles and interleukin-2 to prevent radiotherapy-induced lymphocytopenia in cancer patients.
PMID: 18610754
Ref: Free-from-progression period and overall short preoperative immunotherapy with IL-2 increases the survival of pancreatic cancer patients treated with macroscopically radical surgery.
PMID: 18630487
Ref: Influence of Hsp70 and HLA-E on the killing of leukemic blasts by cytokine/Hsp70 peptide-activated human natural killer (NK) cells.
PMID: 18759005
Ref: Cytokine adjuvanation of therapeutic anti-tumor immunity targeted to cancer mucosa antigens.
PMID: 19956776
Ref: Impact of surgery on immunologic function: comparison between minimally invasive techniques and conventional laparotomy for surgical resection of colorectal tumors.
PMID: 18639228
Ref: Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy.
PMID: 19401694
Ref: Anti-tumor activity of patient-derived NK cells after cell-based immunotherapy--a case report.
PMID: 19549307
Ref: T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis.
PMID: 19570783
Ref: High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer.
PMID: 19723883
Ref: Changes in cytokine and biomarker blood levels in patients with colorectal cancer during dendritic cell-based vaccination.
PMID: 19863224
Ref: The effect of colorectal cancer upon host peripheral immune cell function.
PMID: 19250260
Ref: Association between interleukin-4R and TGF-beta1 gene polymorphisms and the risk of colorectal cancer in a Korean population.
PMID: 19863607
Ref: [Effect of adenovirus-mediated CD/TK double suicide gene system on colorectal cancer growth and cytokines in the tumor microenvironment in mice].
PMID: 20159695
Ref: Interleukin-4 downregulates CD127 expression and activity on human thymocytes and mature CD8+ T cells.
PMID: 20201040
Ref: In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction.
PMID: 20308560
Ref: Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist.
PMID: 20386085
Ref: Netrin-1 regulates Th1/Th2/Th17 cytokine production and inflammation through UNC5B receptor and protects kidney against ischemia-reperfusion injury.
PMID: 20693423
Ref: Dendritic cell vaccination of patients with metastatic colorectal cancer.
PMID: 20816019
Ref: [Influence of FOLFOX regimen on the immunologic function in patients with advanced colorectal cancer].
PMID: 20878571
Ref: Oct1 is a switchable, bipotential stabilizer of repressed and inducible transcriptional states.
PMID: 21051540
Ref: IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer.
PMID: 21357259
Ref: Human colonic myofibroblasts promote expansion of CD4+ CD25high Foxp3+ regulatory T cells.
PMID: 21376048
Ref: Intratumoral injection of interleukin-2 augments the local and abscopal effects of radiotherapy in murine rectal cancer.
PMID: 21443690
Ref: Intraoperative epidural analgesia prevents the early proinflammatory response to surgical trauma. Results from a prospective randomized clinical trial of intraoperative epidural versus general analgesia.
PMID: 21479690
Ref: Nutritional influences in selected gastrointestinal diseases.
PMID: 21734379
Ref: [Inflammatory factors promote the development of colorectal cancer].
PMID: 21873790
Ref: Chemopreventive effects of NSAIDs on cytokines and transcription factors during the early stages of colorectal cancer.
PMID: 22180364
Ref: Combined treatment with bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patients.
PMID: 20820907
Ref: In vivo expansion of naive CD4+ CD25(high) FOXP3+ regulatory T cells in patients with colorectal carcinoma after IL-2 administration.
PMID: 22276195
Ref: Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array.
PMID: 22363134
Ref: Modulation of systemic and intestinal immune response by interleukin-2 therapy in gastrointestinal surgical oncology. Personal experience in the context of current knowledge and future perspectives.
PMID: 22399622
Ref: Circulating regulatory T cells of cancer patients receiving radiochemotherapy may be useful to individualize cancer treatment.
PMID: 22682747
Ref: Human IL18-IL2 fusion protein as a potential antitumor reagent by enhancing NK cell cytotoxicity and IFN-gamma production.
PMID: 22699929
Ref: Overexpression and beta-1,6-N-acetylglucosaminylation-initiated aberrant glycosylation of TIMP-1: a "double whammy" strategy in colon cancer progression.
PMID: 22859303
Ref: LAP+CD4+ T cells are suppressors accumulated in the tumor sites and associated with the progression of colorectal cancer.
PMID: 22879386
Ref: Role of macrophage migration inhibitory factor in the regulatory T cell response of tumor-bearing mice.
PMID: 22972922
Ref: Antitumor effect of murine dendritic and tumor cells transduced with IL-2 gene.
PMID: 23042272
Ref: Activated but not resting regulatory T cells accumulated in tumor microenvironment and correlated with tumor progression in patients with colorectal cancer.
PMID: 22907255
Ref: Angiostatic properties of sulindac and celecoxib in the experimentally induced inflammatory colorectal cancer.
PMID: 23149858
Ref: Cytotoxicity of lymphocytes activated by superantigen toxic-shock-syndrome toxin-1 against colorectal cancer LoVo cells.
PMID: 23340976
Ref: Ex vivo characterization of gammadelta T-cell repertoire in patients after adoptive transfer of Vgamma9Vdelta2 T cells expressing the interleukin-2 receptor beta-chain and the common gamma-chain.
PMID: 23391461
Ref: Tim-3 expression defines regulatory T cells in human tumors.
PMID: 23526963
Ref: Chemopreventive and metabolic effects of inulin on colon cancer development.
PMID: 23820222
Ref: [Effect of Achyranthes bidentata polysaccharides stimulated dendritic cells co-cultured with cytokine induced killer cells against SW480 cells].
PMID: 23847957
Ref: NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells.
PMID: 23902851
Ref: Evaluation of the immune factors in the tumor environment before and after the treatment of cetuximab combined with chemotherapy.
PMID: 24028754
Ref: IL-18-based combinatorial adjuvants promote the intranodal production of CCL19 by NK cells and dendritic cells of cancer patients.
PMID: 24228233
Ref: The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer.
PMID: 23818211
Ref: Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients.
PMID: 24699863
Ref: Immune response to JC virus T antigen in patients with and without colorectal neoplasia.
PMID: 25007286
Ref: PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients.
PMID: 25093496
Ref: Interleukin-18 synergism with interleukin-2 in cytotoxicity and NKG2D expression of human natural killer cells.
PMID: 25292077
Ref: Serum cytokine levels in patients with colorectal cancers according to tumor stages and VEGF gene polymorphism.
PMID: 25713884
Ref: Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects.
PMID: 25552483
Ref: Laparoscopic surgery for colorectal cancer is not associated with an increase in the circulating levels of several inflammation-related factors.
PMID: 25875151
Ref: Lack of significant association between serum inflammatory cytokine profiles and the presence of colorectal adenoma.
PMID: 25884547
Ref: Administration of DNA Encoding the Interleukin-27 Gene Augments Antitumour Responses through Non-adaptive Immunity.
PMID: 26095954
Ref: Regulatory T-cell Response to Enterotoxigenic Bacteroides fragilis Colonization Triggers IL17-Dependent Colon Carcinogenesis.
PMID: 26201900
Ref: Human Mucosa-Associated Invariant T Cells Accumulate in Colon Adenocarcinomas but Produce Reduced Amounts of IFN-gamma.
PMID: 26297765
Ref: Effects of flurbiprofen axetil on postoperative serum IL-2 and IL-6 levels in patients with colorectal cancer.
PMID: 26662445
Ref: Co-operation of alpha-galactosylceramide-loaded tumour cells and TLR9 agonists induce potent anti-tumour responses in a murine colon cancer model.
PMID: 26450924
Ref: Treatment with cyclophosphamide supported by various dendritic cell-based vaccines induces diversification in CD4(+) T cell response against MC38 colon carcinoma.
PMID: 26648160
Ref: Obesity and colorectal cancer: molecular features of adipose tissue.
PMID: 26801617
Ref: Enrichment of Inflammatory IL-17 and TNF-alpha Secreting CD4(+) T Cells within Colorectal Tumors despite the Presence of Elevated CD39(+) T Regulatory Cells and Increased Expression of the Immune Checkpoint Molecule, PD-1.
PMID: 27014625
Ref: Virus-Like Particles Displaying Recombinant Short-Chain Fragment Region and Interleukin 2 for Targeting Colon Cancer Tumors and Attracting Macrophages.
PMID: 27037014
Ref: Analysis of tumor-infiltrating gamma delta T cells in rectal cancer.
PMID: 27053849
Ref: Predictive Value of Growth Factors and Interleukins for Future Liver Remnant Volume and Colorectal Liver Metastasis Volume Growth Following Portal Vein Embolization and Autologous Stem Cell Application.
PMID: 27069178
Ref: Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.
PMID: 27070448
Ref: Tungsten Oxide Nanoplates; the Novelty in Targeting Metalloproteinase-7 Gene in Both Cervix and Colon Cancer Cells.
PMID: 27193257
Ref: Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination.
PMID: 27364122
Ref: Antitumor Effect of Zhihuang Fuzheng Soft Capsules on Tumor-Bearing Mice.
PMID: 27493673
Ref: A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment.
PMID: 27558635
Ref: Determination of a CD4(+)CD25(-)FoxP3(+) T cells subset in tumor-draining lymph nodes of colorectal cancer secreting IL-2 and IFN-gamma.
PMID: 27619682
Ref: Inflammatory regulatory T cells in the microenvironments of ulcerative colitis and colon carcinoma.
PMID: 27622054
Ref: TGF-beta1 promotes colorectal cancer immune escape by elevating B7-H3 and B7-H4 via the miR-155/miR-143 axis.
PMID: 27626488
Ref: An effective cytokine adjuvant vaccine induces autologous T-cell response against colon cancer in an animal model.
PMID: 27669687
Ref: Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15.
PMID: 27777574
Ref: Glatiramer Acetate, Dimethyl Fumarate, and Monomethyl Fumarate Upregulate the Expression of CCR10 on the Surface of Natural Killer Cells and Enhance Their Chemotaxis and Cytotoxicity.
PMID: 27807435
Ref: Functional impairment of infiltrating T cells in human colorectal cancer.
PMID: 27999752
Ref: The Chinese Herbal Mixture Tien-Hsien Liquid Augments the Anticancer Immunity in Tumor Cell-Vaccinated Mice.
PMID: 27252074
Ref: Neuroinflammatory and cognitive consequences of combined radiation and immunotherapy in a novel preclinical model.
PMID: 27893434
Ref: Is still there a role for IL-2 for solid tumors other than melanoma or renal cancer?
PMID: 28000528
Ref: Role of LAP(+)CD4(+) T cells in the tumor microenvironment of colorectal cancer.
PMID: 28210081
Ref: Antitumor and Immunomodulatory Effect of Gastrodia elata on Colon Cancer In Vitro and In Vivo.
PMID: 28231745
Ref: Ameliorative effects of pyrazinoic acid against oxidative and metabolic stress manifested in rats with dimethylhydrazine induced colonic carcinoma.
PMID: 28358223
Ref: FOLFOX regimen plus dendritic cells-cytokine-induced killer cells immunotherapy for the treatment of colorectal cancer: a meta-analysis.
PMID: 28572734
Ref: An Atlas of Human Regulatory T Helper-like Cells Reveals Features of Th2-like Tregs that Support a Tumorigenic Environment.
PMID: 28723576
Ref: miR-625-3p is upregulated in CD8+ T cells during early immune reconstitution after allogeneic stem cell transplantation.
PMID: 28854245
Ref: Circulating inflammatory factors associated with worse long-term prognosis in colorectal cancer.
PMID: 28974887
Ref: Novel 1,4-benzothazines obliterate COX-2 mediated JAK-2/STAT-3 signals with potential regulation of oxidative and metabolic stress during colorectal cancer.
PMID: 29229353
Ref: 6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid attenuates colon carcinogenesis via blockade of IL-6 mediated signals.
PMID: 29448205
Ref: Broccoli and human health: immunomodulatory effect of sulforaphane in a model of colon cancer.
PMID: 29513123
Ref: CD8(+)CXCR5(+) T cells in tumor-draining lymph nodes are highly activated and predict better prognosis in colorectal cancer.
PMID: 29544815
Ref: Enhanced Therapeutic Activity of Non-Internalizing Small-Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination with Targeted Interleukin-2.
PMID: 29691298
Ref: Prognostic roles for IL-2-producing and CD69(+) T cell subsets in colorectal cancer patients.
PMID: 29752720
Ref: Subsite heterogeneity in the profiles of circulating cytokines in colorectal cancer.
PMID: 29801973
Ref: Potential of memory T cells in bridging preoperative chemoradiation and immunotherapy in rectal cancer.
PMID: 29871814
Ref: Mebendazole stimulates CD14+ myeloid cells to enhance T-cell activation and tumour cell killing.
PMID: 30112108
Ref: miR-20a inhibits the killing effect of natural killer cells to cervical cancer cells by downregulating RUNX1.
PMID: 30249397
Ref: Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.
PMID: 30315349
Ref: Doxorubicin resistance induces IL6 activation in the colon cancer cell line LS180.
PMID: 30344742
Ref: Tanshinone IIA promotes IL2-mediated SW480 colorectal cancer cell apoptosis by triggering INF2-related mitochondrial fission and activating the Mst1-Hippo pathway.
PMID: 30372868